Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.39 |
| ▸ | HTR1A | P08908 | 3/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2457303 | 0.94 | HCAR2 (0.45) | HCAR2PDE10AHTR1ASLC6A2SLC6A4 | |
| SCHEMBL32162354 | 0.85 | HCAR2 (0.48) | HCAR2HTR1ASLC6A2SLC6A4NAPRT | |
| SCHEMBL2460605 | 0.85 | HCAR2 (0.48) | HCAR2HTR1ASLC6A2SLC6A4NAPRT | |
| SCHEMBL2457354 | 0.83 | HCAR2 (0.47) | HCAR2PDE10AHTR1ASLC6A2SLC6A4 | |
| SCHEMBL13361555 | 0.82 | HCAR2 (0.46) | HCAR2HTR1ASLC6A2SLC6A4PDK2 | |
| SCHEMBL13361533 | 0.80 | HCAR2 (0.45) | HCAR2HTR1ASLC6A2SLC6A4PDK2 | |
| SCHEMBL2457181 | 0.79 | PDE10A (0.46) | HCAR2PDE10ASPR | |
| SCHEMBL629415 | 0.79 | ESR2 (0.44) | HCAR2PDE10AHTR1ASLC6A2SLC6A4 | |
| SCHEMBL2456867 | 0.79 | HCAR2 (0.46) | HCAR2HTR1ASLC6A2SLC6A4ESR2 | |
| SCHEMBL8314694 | 0.79 | HCAR2 (0.44) | HCAR2HTR1ASLC6A2SLC6A4NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376450-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376450-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376450-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-8759532-B2 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8637500-B2 | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637500-B2 | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637500-B2 | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130253186-A1 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8497265-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497265-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
| WO-2010057126-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010057126-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20090062269-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-20090062269-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| WO-2008051403-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007092364-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062269-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | HCAR2 2/4885PDE10A 1427/4885HTR1A 485/4885 |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | PDE7A, PDE9A, PDE10A | HCAR2 4129/4885PDE10A 3/4885HTR1A 665/4885 |
| US-20130253186-A1 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS | PDE10A, PDE9A, PDE7A | HCAR2 1341/4885PDE10A 1/4885HTR1A 565/4885 |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE4A, PDE7A, PDE4D | HCAR2 3574/4885PDE10A 10/4885HTR1A 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.